Welcome : Guest

Ignyta, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Ignyta, Inc., which is principally involved in Precision Oncology Biotechnology Business. Illustrated with 71 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-64614
Price: $3500
Company Type: Public
Pages: 72
Date: November 2016
Market Data Tables: 71

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Cancer Drugs......2
Table 1: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......2
Table 2: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......3
Cancer Market......4
Table 3: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......4
Table 4: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......5
Table 5: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......6
Table 6: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......7
Table 7: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......8
Table 8: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......9
Table 9: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......10
Table 10: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......11
Cancer Patients......12
Table 11: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......12
Table 12: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......13
Table 13: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......14
Table 14: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......15
Table 15: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......16
Table 16: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......17
Table 17: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......18
Table 18: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......19
Table 19: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......20
Table 20: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......21
Table 21: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......22
Table 22: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......23
Table 23: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......24
Table 24: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......25
Table 25: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......26
Table 26: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......27
Table 27: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......28
Table 28: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......29
Table 29: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......30
Table 30: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......31
Table 31: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......32
Cervical Cancer......33
Table 32: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......33
Table 33: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......34
Hematological Cancer......35
Table 34: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......35
Skin Cancer......36
Table 35: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......36
Cancer-Associated Mucositis......37
Table 36: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......37
Chronic Myelogenous Leukemia (CML)......38
Table 37: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......38
Multiple Myeloma......39
Table 38: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......39
Table 39: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......40
Molecular Diagnostics......41
Table 40: Molecular Diagnostics Market by Application Worldwide (2015) - Percentage Share Breakdown by Value for Blood Screening, Genetics, Infectious Disease, Oncology and Others......41
Table 41: Global Molecular Diagnostics (MDx) Market by Infectious Diseases Therapeutic Area (2015) - Percentage Share Breakdown by Value Sales for CT/NG, Healthcare-associated Infections (HAI), Hepatitis, HIV, Respiratory and Others......42
Table 42: Global Molecular Diagnostics (MDx) Market by Region (2015) - Percentage Breakdown by Value Sales for Americas, EMEA and Pacific......43
Table 43: Molecular Diagnostic Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Disease Inherited, Infectious Diseases, Oncology, Prenatal, and Tissue Typing......44
Table 44: Molecular Diagnostics (MDx) Market by Location of Test Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Banks, Hospitals, Near-Patient, and Reference Labs......45
Table 45: Molecular Diagnostics (MDx) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Bacteriology, Blood Screening, Genomics and Virology......46
Table 46: Molecular Diagnostics (MDx) Market by Technology Worldwide (2015) - Percentage Share Breakdown by Value Sales for Beads, CE Sequencing, Hybrid Capture, ISH, Microarrays, NGS, PCR, Qpcr, TMA, and Others......47
Table 47: Molecular Diagnostics (MDx) Market by Therapeutic Area Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Screening, CT / NG, HAIs, HLA, HPV, Oncology, Viral Load, and Others......48
Table 48: Molecular Diagnostics (MoDx) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Europe, Japan, Korea, US, and Others......49
Table 49: Molecular Diagnostics Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Biochip and Lab-on-a-Chip (LOAC), In Situ Hybridization (ISH), Microarrays, Polymerase Chain Reaction (PCR) and Others......50
Table 50: Molecular Diagnostics Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Infectious Diseases, Inherited Disease, Oncology, Prenatal and Tissue Typing......51
Table 51: Molecular Diagnostics Infectious Diseases Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Active Tuberculosis, Blood Banking, Chlamydia trachomatis (CT), and Neisseria gonorrhoeae (NG), Clostridium difficile, Human Papillomavirus (HPV), Influenza, Panels, S. aureus (SA), and methicillin-resistant S. aureus (MRSA), Viral Load, and Others......52
Table 52: Molecular Diagnostics Test Market by Type in Europe (2015) - Percentage Share Breakdown by Volume for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Methicillin-resistant Staphylococcus aureus (MRSA) and Others......53
Table 53: Spending on Molecular Diagnostics and Genetic Testing by Payer in the US (2015) - Percentage Market Share Breakdown by Value for Cancer, Infectious Diseases, Inhired Conditions and Other......54
Table 54: Molecular Diagnostics Lab Market by Test Complexity in the US (2015) - Percentage Share Breakdown by Volume for Highly Complex w/LDT, Highly Complex, no LDT and Moderately Complex......55
Table 55: Molecular Diagnostics Lab Market by Test Type in the US (2015) - Percentage Share Breakdown by Volume for Both ID & Genetics, Disease, Only and Infectious......56
Table 56: Molecular Diagnostics Market by Segment in the US (2015) - Percentage Share Breakdown by Value Sales for Blood Screening, Genetic Testing Order, Oncology, Virology and Other Infectious Diseases......57
Table 57: Molecular Diagnostic Genetics Laboratories Market by Assay in the US (2015) - Percentage Share Breakdown by Value Sales for Cystic Fibrosis, Epidermal Growth Factor Receptor (EGFR), Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS Gene) and Others......58
Table 58: Number of Molecular Diagnostics Laboratories by CLIA Complexity in the US (2015) - Percentage Market Share Breakdown for Highly Complex, No Laboratory-Developed Test (LDT), Highly Complex, With Laboratory-Developed Test (LDT) and Moderately Complex......59
Table 59: Number of Molecular Diagnostics Laboratories by Testing Type in the US (2015) - Percentage Market Share Breakdown for Genetics Only, Infectious Disease Only and Both Infectious Disease and Genetics......60
Cancer Drugs......61
Table 60: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......61
Table 61: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......62
Table 62: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......63
Table 63: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......64
Table 64: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......65
Breast Cancer Drugs......66
Table 65: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......66
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......67
Table 66: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......67
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......68
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......68
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......69
Molecular Diagnostics......70
Table 69: Market Shares of Leading Molecular Diagnostic Product Manufacturers Worldwide (2015) - Percentage Share Breakdown by Value for Abbott Laboratories, Bayer AG, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Hologic Corporation, Novartis International AG, Qiagen, and Others......70
Table 70: Market Shares of Leading Molecular Diagnostics (MDx) Companies by Value Sales Worldwide (2014) - Percentage Breakdown for Abbott Laboratories, Becton, Dickinson and Co., Cepheid, F. Hoffmann-La Roche Ltd., Hologic Gen-Probe, Inc., Novartis AG, Qiagen N.V., Siemens AG and Others......71
Table 71: Market Shares of Leading Molecular Diagnostics (MDx) Equipment Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Abbott Laboratories, Becton, Dickinson and Company, Cepheid, Inc., Hologic, Inc., Illumina, Inc., Qiagen N.V., Rogers Corporation, Siemens AG, Thermo Fisher Scientific, and Others......72